Autologous Platelet-Rich Plasma Intra-ovarian Infusion in Poor Responders
Recruiting
Phase 2
Phase 3
Interventional Study
Ovary; Anomaly
Infertility, Female
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 35 – 47
- Sex
- Female
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Genesis Athens Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Autologous PRP intra ovarian infusion may improve ovarian response, patients' hormonal profile as well as fresh embryo transfer (ET)-ICSI cycles' outcome in patients presenting with Poor Ovarian Response (POR).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following)
* Age ≥ 40 years
* AMH \< 1.1 ng/ml OR AFC \< 7
* ≤ 3 oocytes with a conventional stimulation protocol)
* Discontinuation of any complementary/adjuvant treatment including hormone repl…
Contacts